于羅欣】到【人力資源】3638791.png)
羅欣藥業(yè) 傳遞健康
于羅欣】到【人力資源】5266177.png)
羅欣藥業(yè) 傳遞健康
于羅欣】到【人力資源】7686575.png)
羅欣藥業(yè) 傳遞健康
于羅欣】到【人力資源】7542710.png)
羅欣藥業(yè) 傳遞健康
于羅欣】到【人力資源】4757407.png)
羅欣藥業(yè) 傳遞健康
山東羅欣藥業(yè)集團股份有限公司招標(biāo)公告
5553680.png)
October 22, 2015, Shandong Luoxin Pharmaceutical Croup Stock Co., Ltd (“Luoxin”) entered into an agreement with CJ HealthCare Corporation (“CJ HealthCare”). The agreement grants Luoxin an exclusive right to develop, manufacture and commercialize its asset CJ-12420 for the treatment of Gastrointestinal acid-related disease in the territory of mainland China.
2015年10月22日，山東羅欣藥業(yè)集團股份有限公司（“羅欣藥業(yè)”）與CJ 醫(yī)藥健康公司 (“CJ HealthCare”)在上海簽訂了合作協(xié)議，該協(xié)議授予羅欣藥業(yè)在中國開發(fā)、生產(chǎn)和商業(yè)化其針對胃腸道酸相關(guān)疾病的候選藥物CJ-12420的獨家權(quán)利。
上圖為羅欣藥業(yè)董事會主席劉保起先生與CJ HealthCare總裁兼首席執(zhí)行官Seok-Hee Kang成功簽約并合影留念
Under the Agreement, Luoxin will be responsible for development, manufacture and commercial activities in the Territory and associated expenses. Terms of the Agreement include up-front payment, and subsequent clinical, regulatory, and performance-based milestone payments. Luoxin will also pay CJ HealthCare double-digit percentage royalties on net sales of CJ-12420 in the Territory. Luoxin and CJ HealthCare have agreed on the initial development plan that will be executed by Luoxin. It is anticipated that the clinical trial application will be submitted in the first half of 2016.
根據(jù)該協(xié)議，羅欣藥業(yè)將負責(zé)該產(chǎn)品在中國的開發(fā)、生產(chǎn)、商業(yè)化及相關(guān)費用。該協(xié)議條款包括首付款、臨床、上市及銷售里程碑款。同時，羅欣藥業(yè)也將向CJ HealthCare支付針對CJ-12420在中國凈銷售額的兩位數(shù)提成。羅欣藥業(yè)及CJ HealthCare已商定先期的開發(fā)計劃并由羅欣藥業(yè)進行執(zhí)行，臨床試驗申請預(yù)計將于2016年上半年提交。
"We are pleased to partner with CJ HealthCare to develop and commercialize CJ-12420 in China," said Baoqi Liu, Chairman of the Board of Luoxin. "CJ-12420 is an excellent fit with Luoxin's commercial capabilities and portfolio, and we believe that we can move CJ-12420 development rapidly as a new treatment option to address the unmet needs of Chinese patients with Gastrointestinal acid-related diseases. Rely on the comprehensive capability of the Luoxin including development, manufacture and commercialization, we expect to bring to more innovative and clinical differentiated medicine to Chinese patients ”
羅欣藥業(yè)董事會主席劉保起先生表示：“很高興CJ HealthCare選擇與我們在中國進行CJ-12420的開發(fā)和商業(yè)化合作，該產(chǎn)品與羅欣藥業(yè)的商業(yè)實力和產(chǎn)品線非常契合，我們相信通過羅欣藥業(yè)對CJ-12420開發(fā)的快速推進，將使其成為解決中國胃腸道酸相關(guān)疾病患者的一項新的治療選擇。同時，依托羅欣藥業(yè)集團包括研發(fā)，生產(chǎn)及商業(yè)化的綜合實力，我們希望把更多創(chuàng)新的具有臨床優(yōu)勢的產(chǎn)品帶給中國的患者。”
"This transaction helps us further our goal of maximizing the value of CJ-12420 by selectively licensing rights to the product outside of Korea," said Seok-Hee, Kang, CJ HealthCare's President and Chief Executive Officer. "Luoxin is a leading pharmaceutical company in China with an impressive track record of achieving development, registration and effectively commercializing pharmaceutical products, especially for the acid inhibition treatment market in China, will achieve a great success in the China market."
Seok-Hee Kang，CJ HealthCare的總裁兼首席執(zhí)行官表示：“在韓國以外的地區(qū)，通過產(chǎn)品授權(quán)的合作方式，將進一步實現(xiàn)CJ-12420價值最大化的商業(yè)目標(biāo)。我們相信憑借羅欣藥業(yè)的綜合研發(fā)能力，注冊管理經(jīng)驗和市場優(yōu)勢，特別是在中國胃腸道市場的能力，必將開發(fā)出該產(chǎn)品在中國市場的巨大潛力”。
CJ-12420 is a potassium-competitive acid blocker (P-CAB) in Phase 3 development for the treatment of reflux esophagitis and other acid-related GI diseases. CJ-12420 competitively inhibits the binding of potassium ions to H+,K+-ATPase in the final step of gastric acid secretion in gastric parietal cells, which has the potential to provide a strong and sustained acid secretion inhibitory effect.
CJ-12420是一種鉀離子競爭性酸抑制劑（P-CAB），目前處于臨床3期階段用于治療反流性食管炎及其他酸相關(guān)腸胃疾病。CJ-12420在胃壁細胞分泌胃酸的最后階段競爭性地阻斷鉀離子與氫離子及鉀離子-三磷酸腺苷酶的結(jié)合，可對胃酸分泌產(chǎn)生強大而持久的抑制效果。
Pursuant to the statistics from IMS, in mainland China, the CAGR (Compound Annual Growth Rate) of Gastrointestinal anti-acids market is about 25% in 2010-2014, and the annual sales revenue reached 2.6 billion US dollars in 2014.
根據(jù)IMS數(shù)據(jù)顯示，中國胃腸道抗酸藥市場于2010年至2014年間的復(fù)合年增長率約為25%，2014年年度銷售收入達到26億美元。
上圖為羅欣藥業(yè)CJ醫(yī)藥健康，CJ-12420簽約儀式現(xiàn)場
About Luoxin
關(guān)于羅欣藥業(yè)
Luoxin is a well-established domestic pharmaceutical company in China, which has the full chain capability of R&D, manufacture, supply, and commercialization. In 2014, sales revenue reached 1B USD. In 2014, Luoxin Shanghai R&D center was set up, with the commitment to enrich current pipelines (generics) with innovative medicines, through in-licensing and strategic partnerships. With the comprehensive capabilities in China market, Luoxin is committed and dedicated to provide good medicines to Chinese patients. For further information, please visit us at www.luoxinbio.com.
羅欣藥業(yè)是一家擁有完善體系的中國本土醫(yī)藥公司，具備完整的研發(fā)、生產(chǎn)、供應(yīng)和商業(yè)化能力，在2014年銷售收入達到10億美元。2014年，羅欣藥業(yè)在上海設(shè)立研發(fā)中心，致力于通過創(chuàng)新藥物的引進與戰(zhàn)略合作，在現(xiàn)有仿制品藥物基礎(chǔ)上完善及加強其產(chǎn)品線。基于在中國市場的的綜合實力優(yōu)勢，羅欣藥業(yè)致力于為中國患者提供優(yōu)良的藥物。更多資料請訪問www.luoxinbio.com.
About CJ HealthCare
關(guān)于CJ HealthCare
CJ HealthCare Corp. is a wholly owned subsidiary of CJ CheilJedang Corp., which is the backbone of Korea's giant CJ Group. Since its establishment in 1984, CJ HealthCare has taken firm leadership in the local pharmaceutical market thanks to its product lineup of prescription drugs such as gastrointestinal, anticancer, circulatory system, diabetes, and kidney disease treatments and over-the-counter (OTC) drugs. CJ HealthCare continues its commitment to R&D and innovation for the healthier future of human beings. CJ HealthCare looks set to secure the product pipelines of new drugs and biologics based on its invaluable human resources with globally competitive R&D competencies by 2020 and globalize its arena through tapping into overseas markets more proactively. CJ HealthCare discovers, develops, manufactures and markets mainly prescription drugs and achieved 435 Million USD with 1,156 employees in 2014. For further information, please visit us at www.cjp.co.kr.
CJ HealthCare Corp.是CJ CheilJedang Corp.的全資子公司，而CJ CheilJedang Corp.為韓國巨擘CJ Group的骨干企業(yè)。自1948年成立以來，CJ HealthCare憑借其處方藥，如腸胃藥、抗癌藥、循環(huán)系統(tǒng)藥、糖尿病藥及腎藥，及非處方藥品組合，于韓國藥品市場獨占鰲頭。CJ HealthCare繼續(xù)致力于研發(fā)及創(chuàng)新，造福人類未來健康生活。CJ HealthCare務(wù)求于2020年基于其寶貴人力資源及具有全球競爭力的研發(fā)能力確保推出新藥品及生物產(chǎn)品系列，并透過更積極進軍海外市場，將業(yè)務(wù)拓展至全球范疇。CJ HealthCare主要物色、開發(fā)、生產(chǎn)及營銷處方藥，于2014年取得4.35億美元，旗下有1,156名雇員。更多資料請訪問www.cjp.co.kr.
Contract 聯(lián)系人
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.山東羅欣藥業(yè)集團股份有限公司
Peter Ji
Business Development Director業(yè)務(wù)發(fā)展總監(jiān)
86(21)50860180 - 8865
or
CJ HealthCare Corporation
Seoung-Pill Shin
Strategy Support Specialist戰(zhàn)略支持專員
82(2) 67402154
系_252x1372941363.jpg)
_500658571_新聞資訊（企業(yè)商用）_gaitubao_1200x322_gaitubao_326x1442098090.jpg)
_500502339_放飛鴿子（企業(yè)商用）_gaitubao_326x1441736598.jpg)